Balyasny Asset Management LLC Autolus Therapeutics PLC Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$3.33 - $5.68 $128,824 - $219,736
-38,686 Reduced 63.49%
22,242 $77,000
Q1 2024

May 13, 2024
BUY
$5.39 - $7.29 $328,401 - $444,165
60,928 New
60,928 $388,000
Q3 2018

Nov 14, 2018
SELL
$20.86 - $33.33 $1.04 Million - $1.67 Million
-50,000 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$25.0 - $27.75 $1.25 Million - $1.39 Million
50,000 New
50,000 $1.34 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $208M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email